Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MASCT-I + ifosfamide
- Development stage
- Unknown
- Lead developer
- HRYZ Biotech
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
MASCT-I + ifosfamide is an investigational combination therapy being studied for advanced and metastatic soft tissue sarcoma. MASCT-I is a novel immunotherapy, possibly a cell-based product, though detailed technical modality is not clearly specified in public records. Ifosfamide is an alkylating agent chemotherapy that works by DNA cross-linking to inhibit cancer cell division, leading to cell death. The combination aims to harness both cytotoxic chemotherapy and an immune-based approach for potentially enhanced antitumor efficacy. This combination is primarily being studied in the context of soft tissue sarcoma, including subtypes such as infantile fibrosarcoma and rhabdomyosarcoma[1][3][5][9].
- Other names
- MASCT-I and ifosfamideMASCT-I combined with ifosfamide
02
Targets
DNA
Beyond the preview
Go deeper on MASCT-I + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MASCT-I + ifosfamide.